Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol UFT oral anticancer agent NDA filing projected for 1998 under licensing agreement with Taiho.

Executive Summary

BRISTOL PROJECTS 1998 NDA FILING FOR UFT FOR COLORECTAL CANCER under a licensing agreement with Taiho Pharmaceutical announced May 10. Under the agreement, Bristol-Myers Squibb will complete Phase III studies of the oral anticancer agent for the colorectal cancer indication and other indications which have not been identified. Bristol will have exclusive rights to the product throughout the world, except in Japan, Spain and several Asia-Pacific countries.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel